Publications by authors named "Lillian Bussema"
The evolution of isocitrate dehydrogenase (IDH)-wildtype glioblastoma (GBM) after standard-of-care therapy remains poorly understood. Here we analyzed matched primary and recurrent GBMs from 59 patients using single-nucleus RNA sequencing and bulk DNA sequencing, assessing the longitudinal evolution of the GBM ecosystem across layers of cellular and molecular heterogeneity. The most consistent change was a lower malignant cell fraction at recurrence and a reciprocal increase in glial and neuronal cell types in the tumor microenvironment (TME).
View Article and Find Full Text PDFIn isocitrate dehydrogenase wildtype glioblastoma (GBM), cellular heterogeneity across and within tumors may drive therapeutic resistance. Here we analyzed 121 primary and recurrent GBM samples from 59 patients using single-nucleus RNA sequencing and bulk tumor DNA sequencing to characterize GBM transcriptional heterogeneity. First, GBMs can be classified by their broad cellular composition, encompassing malignant and nonmalignant cell types.
View Article and Find Full Text PDFBackground: Schwannomas are nerve sheath tumors arising at cranial and peripheral nerves, either sporadically or in patients with a schwannomatosis-predisposition syndrome. There is limited understanding of the transcriptional heterogeneity of schwannomas across genetic backgrounds and anatomic locations.
Methods: Here, we prospectively profile by single-cell full-length transcriptomics tumors from 22 patients with NF2-related schwannomatosis, non-NF2-related schwannomatosis, and sporadic schwannomas, resected from cranial and peripheral nerves.
Cysteine-focused chemical proteomic platforms have accelerated the clinical development of covalent inhibitors for a wide range of targets in cancer. However, how different oncogenic contexts influence cysteine targeting remains unknown. To address this question, we have developed "DrugMap," an atlas of cysteine ligandability compiled across 416 cancer cell lines.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how glioblastoma, a type of brain cancer, interacts with its surrounding environment, particularly focusing on the role of macrophages in promoting mesenchymal-like characteristics in cancer cells.
- Researchers utilized single-cell RNA sequencing and functional experiments to demonstrate that macrophages trigger these changes through the release of a protein called oncostatin M (OSM), which activates specific receptors on glioblastoma cells.
- The findings also reveal that the transformation to mesenchymal-like states is linked with a stronger immune response, including increased activity of T cells and changes in macrophage behavior, suggesting potential avenues for cancer treatment.